Summary & Overview
HCPCS Level II J7518: Mycophenolic Acid, Oral, 180 mg
HCPCS Level II code J7518 denotes an oral formulation of mycophenolic acid, 180 mg. This code identifies a commonly prescribed immunosuppressive medication used in transplant and autoimmune disease management; accurate coding is important for claims processing, pharmacy reimbursement, and utilization monitoring at the national level. Key national payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what J7518 represents clinically and operationally, the typical sites of service where the product is dispensed, and which major payers cover it. The publication summarizes benchmarks for coverage and reimbursement where available, outlines relevant billing considerations for pharmacy and outpatient clinic settings, and flags policy updates affecting HCPCS Level II reporting and oral specialty medication management. Data not included in the input (for example, specific coverage determinations, associated ICD-10 diagnoses, taxonomies, and related codes) are noted as unavailable in the input.
Billing Code Overview
HCPCS Level II code J7518 represents mycophenolic acid, oral, 180 mg. The service is a prescription oral medication for immunosuppression, typically used in outpatient pharmacy settings and administered by patients at home. Typical sites of service include outpatient pharmacies, clinic-based dispensing, and home administration when prescribed for chronic immunosuppressive therapy.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 48-year-old female patient with a history of renal transplant presents for routine outpatient medication management. The transplant team has prescribed oral mycophenolic acid J7518 180 mg tablets as part of her maintenance immunosuppression regimen to prevent allograft rejection. The typical workflow begins with a transplant clinic or specialty pharmacy visit where the clinician documents indication, dosing, potential interactions, and required laboratory monitoring (complete blood count, liver function tests, serum creatinine). The prescription for J7518 is transmitted to a specialty or outpatient pharmacy for dispensing. The usual site of service is an ambulatory clinic or outpatient pharmacy; the medication may also be dispensed in an infusion center when coordinated with other transplant care services. Medication administration is oral self-administration at home with periodic clinic follow-up for therapeutic monitoring and adverse effect surveillance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier; standard billing | Use when no special circumstances apply to the service or supply |